Kanglin Biotec

12/06/2026

🌟 Milestone Announcement: A New Era for Thalassemia Care in Hainan! 🌟

We are thrilled to announce that West China Lecheng Hospital, Sichuan University has been officially approved as a Centre of Excellence for the administration of Kanexthal™, under the innovative Hainan Medical Tourism Policy! 🇨🇳✨

🏛️ A Powerhouse of Medical Excellence
West China Lecheng Hospital is a premier institution co-built by Sichuan University and the People’s Government of Hainan Province. This state-of-the-art facility integrates the world-class resources, research, and clinical expertise of four legendary institutions:
• West China Hospital
• West China Second University Hospital
• West China Hospital of Stomatology
• West China Fourth Hospital

🩸 Transforming Lives with Kanexthal™
Kanexthal™ represents a massive leap forward in hematology. In both clinical trials and real-world settings, it has already been used to successfully treat more than 80 transfusion-dependent β-thalassemia patients, offering them a life-changing path toward transfusion independence and a brighter, healthier future.

🌴 Harnessing the Lecheng, Boao Advantage
Thanks to the unique policies of the Hainan Free Trade Port, patients will now have accelerated access to this cutting-edge therapy at our world-class facility. By combining advanced medical tourism with top-tier clinical care, we are proud to position Hainan as a global hub for medical innovation and patient hope.

"Our designation as a Centre of Excellence is a testament to our commitment to bringing advanced, life-saving therapies to the patients who need them most, faster than ever before."

Join us in celebrating this incredible milestone for rare disease care and medical innovation! 🥂📊

10/06/2026

🌍 Advancing knowledge in

On Thursday, 11 June 2026, the next session of the on Advances in Thalassaemia Care will take place, focusing on:
'Contemporary Management Strategies in Non-Transfusion-Dependent Thalassaemia'.

The webinar will be held from 6:00 PM – 8:00 PM (IST) / 12:30 PM – 2:30 PM (GMT) and will feature Prof. Khaled Musallam, Director of the Thalassemia and Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UAE, as the international expert speaker.

The session will be chaired by Dr. Androulla Eleftheriou, Executive Director of the Thalassaemia International Federation - TIF, with Ms. Shobha Tuli, Secretary of Thalassemics India and TIF's Secretary , providing the context setting. The discussion will be moderated by Dr. Nita Radhakrishnan, Additional Professor and Head of Pediatric Hematology Oncology, PGICH, Noida.

The webinar is organised by the Thalassemics India, the Postgraduate Institute of Child Health, TIF, Noida, ECHO India, and the Pediatric Hematology and Oncology Chapter of the Indian Academy of Pediatrics.

📅 Date: Thursday, 11 June 2026
🕕 Time: 6:00 PM – 8:00 PM (IST) / 12:30 PM – 2:30 PM (GMT)

02/06/2026

A major step forward for thalassemia care in Egypt 🇪🇬

Thalassemia affects thousands of families in Egypt—and recently, we took a significant step toward changing that reality.

We had the honor of meeting online with the Egyptian Drug Authority (EDA). This was more than a meeting—it’s the beginning of a powerful partnership.

Our focus? Moving our gene therapy program from the lab to the lives of those who need it most.

Our goal? A potential one-time treatment that brings lasting relief to patients.

Collaboration turns innovative science into accessible hope.

Here’s to writing a new future for β-thalassemia care—together.

🧬

28/05/2026

📽️ Throwback to a moment that still moves us forward.

This , we're looking back at a message that continues to shape who we are and why we do what we do.

Earlier this month, our Founder and CEO, Dr. Haoqian Wu, shared a heartfelt message with the thalassaemia community — speaking not just about the science of gene therapy, but about the soul of our mission: ensuring that groundbreaking treatments reach every patient who needs them, no matter where they are.

🎬 Watch the video again below.

That message remains just as urgent today. Because every diagnosis still waiting for an answer. Every family still hoping for options. Every caregiver still showing up — they are why Kanglin Bio exists.

Thank you, Dr. Wu, for reminding us that visibility leads to value, and value must lead to action.

We're proud to stand with patients, families, healthcare professionals, and advocates around the world. Together, we are .

🔁 Repost this throwback if you believe in accessible, patient-centred gene therapy for thalassaemia.

27/05/2026

🌙 Eid Al-Adha Mubarak from Kanglin Bio! | كل عام وأنتم بخير

As communities around the world gather to celebrate Eid Al-Adha, the Kanglin Bio family extends our warmest wishes of peace, joy, and prosperity to our global partners, colleagues, and friends celebrating today.

Eid Al-Adha is a beautiful reminder of the values of selflessness, devotion, and unity. At Kanglin Bio, these principles resonate deeply with our core mission—to dedicate our scientific innovations to the service of humanity, bringing hope, renewed health, and accessible healing to patients and communities worldwide.

May this sacred occasion strengthen our shared commitment to collaboration, compassion, and a healthier future for all.

Wishing you, your families, and your loved ones a blessed, safe, and joyous Eid.

Eid Mubarak! ✨

For Humanity

11/05/2026

✨This , we at Kanglin Bio take a moment to reflect on what drives us every day in the lab, in the clinic, and in conversation with patients and families.

🎤We're proud to share a message from our Founder and CEO, Dr. Haoqian Wu. In it, he speaks not only to the science we're building — innovative gene therapies for thalassaemia and beyond — but to a deeper commitment: making sure that what we build reaches those who need it most.

✔️Because transformative science without accessible treatment is only half the story.

🌍Thank you, Dr. Wu, for reminding the thalassaemia community that our work is, and always will be, patient-centred. And thank you to every researcher, clinician, advocate, and family who continues to push for progress — together, we are .

🔗 Read Dr. Wu's full message in the original post below.

08/05/2026

Behind every diagnosis is a story waiting to be heard. Behind every unanswered question is a family searching for hope.

Today, on 2026, we acknowledge what statistics can't capture: the quiet strength of patients navigating chronic treatment, the resilience of caregivers showing up every day, the dedication of healthcare professionals pushing boundaries, and the relentless pursuit of advocates who refuse to let thalassaemia stay in the dark.

👉At Kanglin Bio, we believe science advances fastest when voices are lifted, not lost. That's why we stand with the global community — turning visibility into value, and value into meaningful action.

🌍A Global Community. A Shared Voice.

Let this be the year thalassaemia is .

🔗 Learn more: https://lnkd.in/dR8bsD6S

Today, we raise our voices for every person affected by .

For those diagnosed.
For those still searching for answers.
For those living unseen.

For every patient, every family, every caregiver, every healthcare professional, and every advocate who keeps hope moving forward.

This 2026, we stand united in hope, solidarity, and purpose, honouring every journey, amplifying every voice, and turning a global spotlight on a condition that too often remains in the shadows.

Together, we are .

29/04/2026

✨ Hidden No More: Bringing Hope to Thalassaemia Patients Worldwide

To mark International Thalassaemia Day 2026, we’re hosting a special global webinar to share how gene therapy is opening new possibilities for patients living with transfusion-dependent β-thalassaemia (TDT).

💬 Join us to learn:
✔️ How gene therapy works
✔️ What the treatment journey looks like
✔️ Real-world progress in patient access

🎤 Speaker: Dr. Kee Wee Tan (Ph.D.)

📅 May 12, 2026
⏰ 20:00 (China Time, UTC+8)
💻 Online via Microsoft Teams

👉 Scan the QR code on the poster to register
📩 Webinar details will be sent after registration

If you or someone you know is affected by thalassaemia, this session could be valuable — feel free to share 💙

15/04/2026

🇾🇪🇨🇳 Yemen-China Partnership Brings Hope for Thalassemia Patients

We were honored to hold a virtual meeting with Yemeni health and academic officials, coordinated by the Cultural Attaché of the Yemeni Embassy in Beijing, to discuss Kanexthal™ (KL003) – an advanced gene therapy for β-thalassemia.

🧬 Promising Real World Data of Kanexthal™:
✅ 50+ patients successfully treated
✅ Transfusion independence alleviates burden on blood bank specifically and society on the whole
✅ Significantly lower cost than other gene therapies

🤝 Yemen's priorities: Safety, international recognition, and national capacity building.

✅ Kanglin's commitment: Receiving patients, training, knowledge exchange, and community awareness.

This initiative reflects a shared vision for affordable, advanced treatment and a sustainable healthcare system in Yemen.

🔗 For more details (Arabic): https://www.sawt-alasima.net/news/104182

في إطار جهود تعزيز التعاون الصحي والاكاديمي ونقل التقنيات الطبية المتقدمة، عُقد لقاء افتراضي (عن بُعد) جمع مسؤولين من القطاع الصحي والأكاديمي اليمني م

13/04/2026

【Advancing Hematology-Oncology: Insights from Surabaya 🇮🇳】

We are thrilled to share the highlights from the recent International Guest Lecture & Scientific Seminar hosted by Universitas Katolik Widya Mandala Surabaya (UKWMS). We were honored to participate in this prestigious forum, contributing to the global dialogue on innovative strategies in cellular and gene therapies.

🌟Spotlight on Innovation & Collaboration
The seminar featured key insights into the future of thalassemia and aplastic anemia treatment, bridging the gap between precision diagnostics and life-changing therapies:

Dr. Kee Wee Tan (PhD), representing Kanglin Biotec, delivered a compelling session titled:
"Gene Therapy: A Revolutionary Step in Treating Thalassemia" Dr. Tan explored the transformative potential of gene therapy in addressing the root causes of thalassemia, highlighting our commitment to developing curative solutions for patients worldwide.

Prof. Shunqing Wang (MD, PhD), from Guangzhou First People’s Hospital—Kanglin Bio’s esteemed collaborative clinical site—shared his extensive expertise on:
"Stem Cell Transplantation for Aplastic Anemia: Chinese Experience and Protocol" Prof. Wang’s presentation underscored the vital role of clinical collaboration in refining protocols and improving patient outcomes in complex hematological conditions.

📍Our Commitment
At Kanglin Bio, we believe that international academic exchange is the cornerstone of medical progress. Collaborating with institutions like UKWMS and clinical leaders like Prof. Wang allows us to push the boundaries of biotechnology and bring next-generation therapies to the patients who need them most.

A big thank you to the organizers at UKWMS and the Ministry of Health Republic of Indonesia for fostering such an impactful scientific exchange!